IBI939

BIOLOGICAL3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Advanced Lung CancerAdvanced Malignancies

Phase 1

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

CompletedNCT04353830

Innovent Biologics (Suzhou) Co. Ltd.Advanced Malignancies

Start: 2020-05-22End: 2022-05-11Updated: 2023-03-01

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

CompletedNCT04672369

Innovent Biologics (Suzhou) Co. Ltd.Advanced Lung Cancer

Start: 2021-06-06End: 2023-06-01Updated: 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

CompletedNCT04672356

Innovent Biologics (Suzhou) Co. Ltd.Advanced Lung Cancer

Start: 2021-01-25End: 2023-06-01Updated: 2023-06-22

Related Papers

A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results.

Journal of Clinical Oncology2023-06-012 citations